Stay updated on Blinatumomab & Pembrolizumab in B-ALL Clinical Trial

Sign up to get notified when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The clinical trial record for blinatumomab plus pembrolizumab in adults with relapsed or refractory B-cell ALL is displayed, with study details, outcome measures, eligibility criteria, locations, and supporting documents.
    Difference
    58%
    Check dated 2026-11-11T01:56:59.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page remains a 403 Forbidden error page instead of showing the clinical study record. The footer’s site revision label changes from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-04T00:21:24.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    An NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears on the error page, and the site revision advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T00:24:58.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-07T00:39:40.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Access to the study page is blocked by a 403 Forbidden error, replacing the trial content with a minimal error screen and a Home link.
    Difference
    19%
    Check dated 2026-09-23T00:46:38.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page was updated to revision 3.7.0, replacing the previous 3.6.6. This reflects a software release without changes to the displayed study content.
    Difference
    0.1%
    Check dated 2026-09-15T23:37:50.000Z thumbnail image

Stay in the know with updates to Blinatumomab & Pembrolizumab in B-ALL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.